Singh et al. reported that leucine restriction was not sufficient to inhibit mammalian target of rapamycin (mTOR) signaling in most BC cell lines, but was associated with activation of the survival molecule Akt, making leucine deprivation an undesirable approach for BC therapy (Singh et al., 2011). This evidence concerns the gene AKT1 and breast cancer.